Opening book details…
Can I read Deuterated Drugs and Biomarkers in the COVID-19 Pandemic on EtoBox?
Deuterated Drugs and Biomarkers in the COVID-19 Pandemic by Ross D. Jansen-van Vuuren; Luka Jedlovčnik; Janez Košmrlj; Thomas E. Massey; Volker Derdau is a Engineering article available to read on EtoBox.
What is Deuterated Drugs and Biomarkers in the COVID-19 Pandemic about?
Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially identified in Wuhan (China) in December 2019, COVID-19 rapidly spread globally, resulting in the COVID-19 pandemic. Carriers of the SARS-CoV-2 can experience symptoms ranging from mild to severe (or no symptoms whatsoever). Although vaccination provides extra immunity toward SARS-CoV-2, there has been an urgent need to develop treatments for COVID-19 to alleviate symptoms for carriers of the disease. In seeking a potential treatment, deuterated compounds have played a critical role either as therapeutic agents or as internal MS standards for studying the pharmacological properties of new drugs by quantifying the parent compounds and metabolites. We have identified >70 examples of deuterium-labeled compounds associated with treatment of COVID-19. Of these, we found 9 repurposed drugs and >20 novel drugs studied for potential therapeutic roles along with a total of 38 compounds (drugs, biomarkers, and lipids) explored as internal mass spectrometry standards. This review details the synthetic pathways and modes of action of these comp
Who reads Deuterated Drugs and Biomarkers in the COVID-19 Pandemic?
It is typically read by researchers, students, and practitioners in Engineering.
- Author
- Ross D. Jansen-van Vuuren; Luka Jedlovčnik; Janez Košmrlj; Thomas E. Massey; Volker Derdau
- Publisher
- American Chemical Society (ACS)
- Published
- 2022
- Language
- EN
- Field
- Engineering (Physical Sciences)